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ABSTRACT 
Objective: In 2013, Mozambique adopted Option B+, universal lifelong antiretroviral therapy (ART) 
for all pregnant and lactating women, as national strategy for prevention of mother-to-child trans-
mission of HIV. We analyzed retention in care of pregnant and lactating women starting Option B+ in 
rural northern Mozambique.  
Methods: We compared ART outcomes in pregnant ("B+pregnant"), lactating ("B+lactating") and 
non-pregnant-non-lactating women of childbearing age starting ART after clinical and/or immuno-
logical criteria ("own health") between July 2013 and June 2014. Lost to follow-up was defined as no 
contact >180 days after the last visit. Multivariable competing risk models were adjusted for type of 
facility (type 1 vs. peripheral type 2 health center), age, WHO stage and time from HIV diagnosis to 
ART.  
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Results: Over 333 person-years of follow-up (of 243 "B+pregnant", 65"B+lactating" and 317 "own 
health" women), 3.7% of women died and 48.5% were lost to follow-up. "B+pregnant" and 
"B+lactating" women were more likely to be lost in the first year (57% vs. 56.9% vs. 31.6%; p<0.001) 
and to have no follow-up after the first visit (42.4% vs. 29.2% vs. 16.4%; p<0.001) than "own health" 
women. In adjusted analyses, risk of being lost to follow-up was higher in “B+pregnant” (adjusted 
subhazard ratio [asHR]: 2.77; 95% CI: 2.18-3.50; p<0.001) and “B+lactating” (asHR: 1.94; 95% CI: 
1.37-2.74; p<0.001). Type 2 health center was the only additional significant risk factor for loss to fol-
low-up.  
Conclusions: Retaining pregnant and lactating women in option B+ ART was poor; losses to follow-
up were mainly early. The success of Option B+ for prevention of mother-to-child transmission of 
HIV in rural settings with weak health systems will depend on specific improvements in counseling 
and retention measures, especially at the beginning of treatment.  
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INTRODUCTION 
Mozambique has one of the highest HIV prevalences in the world, reaching 10.8% among adults 
aged 15 to 49 years. Of the 190,000 infected children (1), more than 90% acquired HIV through ver-
tical transmission. The risk of mother-to-child transmission (MTCT) of HIV can be reduced to <5% 
through a combination of preventive measures, including antiretroviral therapy (ART) for the ex-
pectant mother and her newborn child and hygienic delivery conditions (2, 3).  
 
In 2013, WHO recommended Option B+ as the preferred strategy for the prevention of mother-
to-child transmission (PMTCT) of HIV. Option B+ consists of lifelong ART for all HIV-infected pregnant 
and lactating women (PLW), irrespective of their clinical status or CD4 cell count. This strategy is ex-
pected to improve the clinical prognosis of HIV-infected women, to reduce the incidence of AIDS-
related conditions and to significantly reduce MTCT (4, 5). Most importantly, Option B+ simplifies 
PMTCT strategies and avoids the reliance on CD4 count measurements, which is an important barri-
er to the timely initiation of ART in many rural African settings (6, 7). Several studies have also shown 
its cost-effectiveness (8-12). Despite initial optimistic data on retention in Malawi (13), other reports 
showed that high losses to follow-up (LTFU) and poor adherence to ART could be major drawbacks 
of this strategy (14, 15). In a recent analysis of SolidarMed ART programs in Southern Africa, includ-
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ing health centers in rural Mozambique, LTFU in general HIV care, especially after the first visit, was 
extremely high (16). Early LTFU is of particular importance as it also seems to be a bottleneck for re-
tention in Option B+ (15).  
Option B+ was adopted as the National PMTCT strategy by the Mozambican National HIV pro-
gram in 2013. However, only few studies have assessed the challenges of implementing such a strat-
egy in rural sub-Saharan African settings with poor and undersupplied health care systems (17). We 
evaluated retention in care of PLW starting ART under Option B+ in rural Mozambique and com-
pared their outcomes with those of women of childbearing age starting ART for their own health. 
We analyzed retention in care from the start of the implementation of Option B+ in decentralized 
clinical settings in Mozambique, allowing early feedback to national health authorities. We also in-
cluded a comparison with a historical cohort of pregnant women who started lifelong ART under Op-
tion A for their own health at Chronic Diseases Units/HIV clinics.  
 
PATIENTS AND METHODS 
Setting 
Ancuabe District is situated in the Northern Mozambican Province of Cabo Delgado, where HIV infec-
tion accounts for at least 20% of the deaths in the province (18). In Ancuabe district, about 125,000 
people live in 64 villages and in Ancuabe town (19), of whom 5,600 persons are estimated to be in-
fected with HIV (20). Ancuabe has no hospital but two big type 1 health centers (HC) and 4 peripher-
al type 2 HC, where two doctors and 48 health care providers work, including 12 midwives, 8 of 
whom are trained to provide HIV care and treatment. Type 1 HC have inpatient services and are led 
by a physician, whereas peripheral type 2 HC only have outpatient services and are led by a non-
physician clinician. Option B+ has been implemented in the three HC offering ART in Ancuabe since 
mid-June 2013, the two type 1 HC and the biggest type 2 HC. The catchment populations of the two 
type 1 HCs are 30,394 (Ancuabe Town HC) and 40,600 (Metoro HC), and the type 2 HC (Meza HC) 
serves 14,568. Metoro HC has good road access, whereas Ancuabe Town and Meza HC have to be 
reached using unpaved roads. In 2013, PLW starting ART under Option B+ were prescribed 
zidovudine (AZT) +lamivudine (3TC) + efavirenz (EFV), whereas adults starting ART for their own 
health received AZT+3TC+nevirapine (NVP). From January 2014 onwards, tenofovir (TDF)+3TC+EFV 
was given to all ART-eligible individuals if not contraindicated. Infants born to mothers under Option 
B+ receive 4 weeks of AZT syrup. Since Option B+ started, a one-stop strategy is implemented: PLW 
are seen by one of the midwives at an integrated antenatal clinic that includes HIV care. Four mid-
wives were trained to give ART at Ancuabe, 3 in Metoro and 1 in Meza HC. All received comprehen-
sive HIV care and treatment training as by the National HIV Program. Nonpregnant nonlactating HIV-
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infected women are attended at the Chronic Diseases Units/HIV clinics by a nonphysician clinician. 
Before Option B+ implementation, pregnant women starting ART for their own health were also at-
tended at Chronic Diseases Units/HIV clinics. Despite the different staffing, antenatal clinics and 
Chronic Diseases Units/HIV clinics were comparable as they were located in the same facility and 
provided daily service with similar availability of laboratory and treatment services. All HC offered 
point-of-care HIV testing at different testing points following national guidelines. CD4 testing was 
centralized at Ancuabe HC since mid 2012 where a PIMA® machine was located; CD4 samples from 
other HC were collected and transported to Ancuabe HC weekly. Adherence counselling was done by 
the ART prescriber and by HIV activists located at every antenatal and HIV clinic in the two type 1 HC 
and by a single HIV activist shared by the two clinics at the type 2 HC. The national HIV program rec-
ommends follow-up visits at 1 week after ART initiation and monthly thereafter for pregnant women 
and at 2 weeks, 1, 2 and 6 months and every 6 months thereafter for nonpregnant women (21). Ac-
tive tracing was started two weeks after a patient did not show up for a scheduled pick up of HIV 
drugs, according to National recommendations. It consisted of a home visit by an HIV activist. The 
same tracing procedure was followed for women seeking HIV care for their own health and for Op-
tion B+ women.  
 
Study population and data collection 
We included all ART-naïve, HIV-infected women of childbearing age (15-50 years) who started ART 
between 1st July 2013 and 30th June 2014 in any of the three health centers providing Option B+ 
PMTCT in Ancuabe district. In a secondary analysis, we included an additional group of pregnant 
women who received lifelong ART under Option A (those with CD4 ≤350 and/or III or IV WHO stage) 
between January 2011 and June 2013 at the same HC. ART start and follow-up of pregnant women 
under option A were done at the Chronic Diseases Units/HIV clinics. We did not include pregnant 
women starting prophylaxis with AZT from week 14 plus single dose NVP at onset of labour under 
option A (those with CD4 >350 and I or II WHO stage) because data were not available. Most preg-
nant women received HIV testing and counselling at the antenatal care visit; lactating women were 
identified mainly when presenting at the clinic for infant follow-up or post-partum visit.  
 
Routine programmatic data from patients starting ART were collected prospectively since 2009, 
in the framework of a collaboration between SolidarMed, a Swiss-based NGO, IeDEA (International 
Epidemiological Databases for Evaluation of AIDS) (22) and the Pemba Operational Research Nucle-
us. Data were collected from the medical charts by two trained data clerks using a Microsoft Access® 
database; patient data were anonymized to ensure privacy. The study received approval from the 
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Mozambican National Bioethics Committee and all patients provided written informed consent be-
fore the data were entered into the database. The study was also approved by the Operational Re-
search Committee of SolidarMed.  
To ensure quality of data, one of the investigators (JLG) checked the antenatal care clinic regis-
tries to ensure the pregnant/breastfeeding status of each woman was correctly recorded and per-
formed a review of a subsample of patient charts. Data analyses were done using SPSS 15.0 (SPSS 
inc, Chicago, Illinois) and the R© "cmprsk" package (23, 24).  
 
Outcomes and definitions 
Patients who did not return to care for more than 180 days after their last visit were considered 
LTFU (25). For the comparison with the historical cohort of Option A pregnant women we used a 
prospective LTFU definition (26). Patients who missed their first follow-up visit after ART start and 
did not return to care for more than 180 days were considered to have ‘no-follow up after ART initia-
tion’ (NFU). Patients were followed from initiation of ART to the date of the outcome of interest 
(death, LTFU), or database closure (31st December 2014), whichever happened first. A sensitivity 
analysis was carried out using a 90-day definition for LTFU or NFU. Patients transferred out were 
considered as active and were censored at the time of the transfer. All self-reported ART interrup-
tions were recorded in the database. However, ART adherence was not assessed directly.  
 
Participants were classified as:  
 “B+ pregnant”: pregnant women starting ART under Option B+ 
 “B+ lactating”: breastfeeding women starting ART under Option B+ 
 “Own health”: non-pregnant non-lactating women starting ART following clinical (WHO stage 
III/IV) and/or immunological criteria (CD4<350 cells/mm3) 
 “A pregnant”: pregnant women starting lifelong ART (triple ARVs) under Option A 
betweenJanuary 2011 and June 2013.  
 
 
Statistical analyses 
Baseline characteristics were compared between the different patient groups. Categorical variables 
were expressed as absolute frequencies and percentages. Continuous variables were expressed as 
means and standard deviation (SD) or medians and interquartile ranges (IQR). One sample Kolmogo-
rov-Smirnov tests were performed to assess if variables were distributed normally. Normally distrib-
uted numeric parameters were compared between groups using the t test or ANOVA. Mann–
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Whitney U test or Kruskal-Wallis tests were used for non-normal variables. Categorical variables 
were compared between groups using the Pearson Chi-squared test or Fisher´s exact test if the 
group was small.  
Adjusted odds ratio (aOR) of NFU between women from the “B+ pregnant”, “B+lactating” and 
“own health” groups were calculated using multivariable logistic regression. Probability of LTFU and 
death in each group were analyzed using cumulative incidence functions (CIF) and significance eval-
uated with Gray's test (27). Multivariable competing risk regression was used to model the adjusted 
sub-distribution hazard ratio (asHR) of CIF as proposed by Fine and Gray (28, 29). A second set of 
analyses using the same regression models were performed to compare outcomes between “A 
pregnant” and “B+ pregnant” women. All multivariable models were adjusted for type of facility (HC 
type 1 vs. type 2), age, WHO stage and time from HIV diagnosis to ART initiation. P values <0. 05 
were considered statistically significant.  
 
RESULTS 
Baseline characteristics 
625 women of childbearing age started ART in Ancuabe district between July 2013 and June 2014. Of 
these, 308 initiated ART under Option B+ (243 “B+ pregnant”, 65 “B+ lactating”) and 317 for their 
own health. Baseline characteristics were similar between B+ pregnant and B+ lactating women, ex-
cept for time between HIV diagnosis and ART start, which was longer in lactating women (18 vs. 8 
days) (Table 1). B+ pregnant were younger (p<0.001), had higher baseline CD4cell counts (p<0.001) 
and were less likely to be inWHO stage III or IV (p<0.001) than women in the “own health” group. 
Time between HIV diagnosis and ART start was longest in the “own health” group (44 days). CD4 
availability was higher in the “own health” group (82.0%), than in the “B+ pregnant” (39.1%) and the 
“B+ lactating” (56.9%) groups (Table 1).  
 
Retention in the different study groups 
Over 333 women-years of follow-up, 3.7% of women died  and 48.5% were LTFU. Among the latter, 
25.6% were lost after the first visit (NFU). Median follow-up was 47 (interquartile range [ (IQR]: 1-
245) days in “B+ pregnant”, 185 (1-399) in “B+ lactating” and 239 (59-399) days in the “own health” 
group. Overall 1-year retention was 61.9% in women treated for their own health, 40.4% in the B+ 
lactating group and 41.8% in the “B+ pregnant” group (Figure 1). Death occurred in 6.3% of women 
in the “own health” group, 2.7% in the “B+ lactating” group and 1.2% in the “B+ pregnant” group 
(p<0. 001). B+ pregnant and lactating women were more likely to be LTFU in the first year (57% vs. 
56.9% vs. 31.6%; p<0. 001) and to have no follow-up after the first visit (42.4% vs. 29.2% vs. 16.4%; 
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p<0. 001) than women starting ART for their own health. Figure 2 shows the cumulative incidence of 
death and LTFU in the three study groups.  
In adjusted analyses, the risk of LTFU was higher in B+ pregnant women (asHR: 2.77; 95% CI: 
2.18-3.50; p<0.001) and B+ lactating women (asHR: 1.94; 95% CI: 1.37-2.74; p<0.001) than those 
who initiated ART for their own health (Table 2). Women who started ART at a peripheral type 2 HC 
were also more likely to be LTFU (asHR: 1.45; 95% CI: 1.17-1.80; p=0.002). The risk of NFU was higher 
in B+ lactating women (aOR: 2.36; 95% CI 1.23-4.52; p=0.01) and B+ pregnant women (aOR: 4.07; 
95% CI 2.53-6.56; p<0.001) than women in the “own health” group. A sensitivity analysis using the 
90 days LTFU definition yielded similar results (Suppl. Tables 1 and 2; Supplemental Material). A sen-
sitivity analysis adjusted by individual health center showed no differences between the two type 1 
HCs (Suppl. Table 4, Supplemental Material).  
When we compared the two groups of women starting ART under Option B+, B+ pregnant 
women tended to be more likely to have NFU (42.4% vs. 29.2%; aOR 1.73, 95% CI 0.95-3.17; p=0.07) 
and to be LTFU (67.5% vs. 55.4%; asHR 1.2; 95% CI: 1.03-1.96; p=0.03) than B+ lactating women.  
 
Comparison of outcomes with historical Option A cohort 
Seventy-four pregnant women started ART under Option A between January 2011 and June 2013. 
Pregnant women under Option A were less likely to have started ART at a peripheral type 2 HC 
(p<0.001) or to have an available CD4 cell count (p<0.001) but were more likely to have WHO stage 
III/IV (p<0.001) than “B+ pregnant” women (Table 1). B+ pregnant women had higher baseline CD4 
cell counts (p<0.001) and a shorter time from HIV diagnosis to ART initiation (8 vs. 51 days; p<0.001). 
In adjusted analyses, B+ pregnant women were more likely to be LTFU (asHR: 1.91; 95% CI:1.40-2.60; 
p<0.001) and to have NFU (aOR: 3.33; 95% CI 1.50-7.40; p=0.003) than pregnant women on ART un-
der Option A (Table 3). A sensitivity analysis using the 90-day LTFU definition yielded similar results 
(Suppl. Table 3; Supplemental Material). 
We performed a subgroup analysis comparing pregnant women starting ART under Option A 
(n=74) with the subgroup of B+ pregnant women that fulfilled clinical and/or immunological criteria 
for starting ART for their own health (those with CD4 <350 and/or WHO stage III/IV; n=23). In adjust-
ed analyses, B+ pregnant women with clinical and/or immunological criteria for ART start were still 
more likely to be NFU (aOR: 3.61; 95% CI 1.15-11.33; p=0.03) than pregnant women on ART under 
Option A (Suppl. Table 5; Supplemental Material).  
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DISCUSSION 
In rural Mozambique, pregnant women who started ART under option B+ were three times as likely 
to be LTFU as women treated for their own health. A large proportion of those losses occurred early: 
close to half of them did not return to the clinic after the day of ART initiation. Compared to out-
comes from a historical cohort of option A pregnant women on ART, the risk of NFU was more than 
triple in B+ pregnant women.  
Less than half of the B+ women were retained in care during the first year after ART start. These 
estimates remained similar when using a more stringent definition of LTFU (90 days). High LTFU 
rates have been described in pregnant women under option A and B , therefore suggesting that 
some of the factors underlying this poor retention may be a general problem of PMTCT and not spe-
cific to Option B+. However, the higher LTFU rate found in pregnant women starting ART under Op-
tion B+ compared to those starting under Option A may suggest that there could be factors specific 
to this new strategy, such as the lack of sufficiently trained staff or the short time between HIV diag-
nosis and ART start (32% of B+ PLW were started on ART the day they were diagnosed). Improve-
ment of the District HIV program (ART regimens, CD4 availability) with time should have in any case 
benefited retention of Option B+ women. We would like to point out that most LTFU were very early 
losses (NFU), possibly related to the short time between diagnosis and ART start, and possibly indi-
cating that many of those women never even got ART started.  
We found higher overall LTFU rates than other studies (14, 15) but similar to previous reports 
from this rural setting and from other regions in Mozambique, where a high and increasing attrition 
rate during the ART expansion process in the country has been reported (32). Undocumented trans-
fers (33) or deaths could also partly explain this very high LTFU rate. Health system factors such as 
high direct and indirect costs of receiving care and insufficient expansion in the number of health 
staff could also have played a major role (34). Although capacity-building and task shifting was im-
plemented through various trainings, midwives still had very little experience in ART initiation and 
supervision was scarce.  
Stigma and absence of community support may also have negatively contributed to retention 
(35). In Mozambique, a strategy of community ART distribution through self-forming groups of pa-
tients was shown to be quite successful (36-38), but pregnant women are excluded from these 
groups as they need close clinical follow-up. Despite the common counselling policy for all groups, 
more experienced counsellors and longer time available for counselling in the Chronic Diseases 
Units/HIV clinics may have contributed to the lower attrition rate of women seeking HIV care for 
their own health and Option A pregnant women. Active tracing was designed following national rec-
ommendations but was inconsistently done due to lack of transport and staff. No specific tracing 
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strategy was designed for B+ women. Our results suggest that an improved and focused tracing 
strategy may be needed for Option B+ women.  
We found better retention of B+ lactating women compared to B+ pregnant women. Other 
studies have also reported a higher attrition rate in pregnant women (15). Women who start while 
lactating are probably a selection of those who are more motivated for ART so are more likely to be 
retained, as opposed to those who start during pregnancy who would be more likely to just take 
treatment until the baby is born.  
Our study is among the first ones to compare retention of pregnant women starting ART before 
and after Option B+ implementation. One of the main limitations of most studies assessing out-
comes of Option B+ is their inability to compare results with those of pregnant women in option A 
during the same time period. We tried to address this gap by comparing our results with women un-
der option A before B+ started. Protocols in terms of testing procedures, notification of results, or 
subsequent tracing did not differ between Option B+ and Option A women. Main differences be-
tween Option A and B+ were therefore the type of staff and clinic where they were attended as well 
as the recommendation to initiate early ART after diagnosis. We performed a subgroup analysis in-
cluding only B+ pregnant women that would have been eligible for ART under Option A; differences 
in retention in that subgroup analysis may be mostly attributable to implementation and program-
matic factors (such as an insufficient and not enough experienced staff or a very early ART start 
without proper counselling and address of adherence obstacles). However, residual confounding 
may still be important. Unfortunately, outcomes of Option A pregnant women not eligible for ART 
could not be assessed as only data from patients on ART were available. We also did not have data 
on women LTFU before ART initiation. In a large Mozambican study, only 31% of eligible individuals 
started ART within 90 days (39); Option B+ may have reduced these pre-ART drop-outs at the ex-
pense of higher rates of LTFU among patients in HIV care. Another limitation of our study was that 
we were not able to determine if pregnant women were LTFU before or after birth. Other studies 
have suggested worse adherence in the postpartum period pointing out the need for retention 
measures adapted to post-delivery situations (30, 40). Unfortunately, we could not analyze out-
comes according to CD4 values as these were often missing. Information about education, ethnicity, 
marital status or household socioeconomic status of women, that could be a valuable addition to 
understanding potential reasons for LTFU, was not available. Finally, our cohort was limited to a sin-
gle rural district and, therefore, our results may not be generalizable at the country-level.  
The high rate of LTFU described in our study could have severe consequences in terms of verti-
cal transmission of HIV. Community-driven approaches or family-focused approaches could improve 
retention of pregnant women (41, 42). Community ART dispensing programs have shown to improve 
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retention of HIV-infected patients in many Sub-Saharan African countries (43) but adapted solutions 
for PLW should be sought. Health system strengthening and ensuring that sufficient workforce is 
availableare key for this PMTCT strategy in such settings. Although the one-stop strategy has un-
questionable advantages for PLW, shortage of sufficient skilled health staff may hamper its success 
and lead to worse retention rates when compared to those in ART clinics (44). Future research 
should evaluate bottlenecks in the HIV care cascade and factors affecting retention to help design 
strategies to address high attrition in these women.  
 
CONCLUSIONS 
Our study shows very high proportions of early losses to follow-up in patients initiating ART under 
the option B+ strategy in rural Mozambique. These results underline some of the challenges related 
to the implementation of this strategy in settings with weak health care systems, insufficient ART 
counseling and retention measures. Our findings support the need for innovative strategies to im-
prove retention as well as new service delivery models to address the barriers to successful HIV care 
for PLW.  
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 B+ pregnant 
(n=243) 
B+ lactating 
(n=65) 
p
1
 Own health 
(n=317) 
p
2
 A pregnant 
(n=74) 
p
3
 
Followed at a type 
1 HC (%)  
179 (73.7%) 45(69.2%) 0.48 219 (69.1%) 0.24 71(95.9%) <0.001 
HC 
Ancuabe  53 17 
0.45 
119 
<0.001 
46 
<0.001 Metoro 126 28 100 21 
Meza 64 20 98 3 
 NA 0 0  0  4  
WHO stage III-IV 
(%) 
8 (3.3) 4(6.2%) 0.39 117(36.9%) <0.001 27(36.5%) <0.001 
CTX prophylaxis 
(%) 
187 (77.0) 40(61.5%) 0.01 275(86.8%) 0.002 58(78.4%) 0.798 
Median age in 
years(IQR) 
24 (20-30) 25 (20-30) 0.55 30 (24-37) <0.001 26 (23-30) 0.120 
Baseline CD4 avail-
able (%) 
95 (39.1) 37(56.9%) 0.01 260(82.0%) <0.001 48(64.9%) <0.001 
Median CD4 count 
in cell/mm
3
 (IQR) 
495 (373-
664) 
593 (317-
795) 
0.52 276 (158-
395) 
<0.001 358 (251-
579) 
<0.001 
Mean BMI at ART 
start in kg/m
2
(sd) 
22.21±3.08 21.25±2.87 0.07 20.02±3.06 <0.001 23.10±3.95 0.059 
Mean Hb level in 
g/dL (sd) 
9.97±1.50 10.48±1.66 0.13 9.86±1.97 0.61 10.79±1.43 0.173 
Median time from 
HIV diagnosis to 
ART start in days 
(IQR)  
8 (0-27) 18 (4-120) 0.001 44 (19-154) <0.001 51(23-114) <0.001 
Table 1. Characteristics of pregnant and lactating women starting antiretroviral therapy (ART) under option B+, women of 
childbearing age starting ART for their own health and pregnant women starting lifelong ART under Option A. 
1
: for the 
comparison B+ pregnant vs. B+ lactating; 
2
: for the comparison "B+ pregnant" vs. "Own health". 
3
: for the comparison "B+ 
pregnant" vs. "A pregnant". BMI: body mass index; CTX: co-trimoxazole; Hb: hemoglobin; HC: health center; NA: not avail-
able; IQR: interquartile range; sd: standard deviation 
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 Multivariable (adjusted) analyses 
NFU  LTFU  
aOR (95% CI) p value asHR (95% CI) p value 
ART group Own health Reference  Reference  
B+ pregnant 4.07 (2.53-6.56) <0.001* 2.77 (2.18-3.50) <0.001* 
B+ lactating 2.36 (1.23-4.52) 0.01* 1.94 (1.37-2.74) <0.001* 
WHO stage I or II Reference 0.14 Reference 0.77 
III or IV 1.50 (0.87-2.60) 1.05 (0.75-1.47) 
Time from HIV diagnosis 
to ART start 
>10 days Reference 0.35 Reference 0.13 
≤10 days 1.22 (0.80-1.84) 1.19 (0.95-1.50) 
Age >25 years Reference 0.97 Reference 0.73 
≤25 years 1.01 (0.69-1.47) 0.96 (0.78-1.20) 
HC type Type 1 Reference 0.31 Reference <0.001* 
Peripheral type 2 1.23 (0.82-1.84) 1.45 (1.17-1.80) 
   
Table 2. Predictors of no-follow-up (NFU) and lost-to-follow-up (LTFU) after start of antiretroviral therapy (ART) during the 
July 2013 and June 2014 period using a 180-days definition to consider a patient LTFU or NFU. HC: health center; *: statisti-
cally significant 
 
 Multivariable (adjusted) analysis 
NFU  LTFU 
aOR (95% CI) p value asHR (95% CI) p value 
Start of ART under Option A Reference 
0.003* 
Reference 
<0.001* 
Option B+  3.33 (1.50-7.40) 1.91 (1.40-2.60) 
WHO stage I or II Reference 
0.29 
Reference 
0.51 
III or IV 0.56 (0.19-1.67) 0.86 (0.55-1.35) 
Time from HIV diagnosis 
to ART start 
>10 days Reference 
0.52 
Reference 
0.12 
≤10 days 1.18 (0.71-1.95) 1.23 (0.95-1.60) 
Age >25 years Reference 
0.58 
Reference 
0.52 
≤25 years 0.87 (0.53-1.42) 0.92 (0.72-1.18) 
HC type Type 1 Reference  
0.55 
Reference 
0.16 Peripheral type 
2 
1.19 (0.67-2.11) 1.23 (0.92-1.63) 
Table 3. Predictors of no-follow-up (NFU) and lost-to-follow-up (LTFU) after start of ART when comparing pregnant women 
starting antiretroviral therapy (ART) under Option A and under Option B+ using a 180-days definition to consider a patient 
LTFU or NFU. HC: health center; *: statistically significant 
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